Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
11
×
life sciences
national blog main
san francisco blog main
11
×
boston blog main
boston top stories
national top stories
new york blog main
national
new york top stories
san diego blog main
san francisco top stories
wisconsin blog main
wisconsin top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
clinical trials
cancer
eli lilly
ipo
novartis
cancer immunotherapy
crispr
deals
drugs
europe blog main
investing
loxo oncology
What
new
11
×
ipo
bio
companies
drug
fda
roundup
cancer
life
medicines
science
therapeutics
approval
biotech
class
crispr
drugs
group
investors
isn’t
migraine
million
momentum
raised
research
targets
venture
week
won
years
activity
allogene
amgen
approvals
approved
arguments
arrival
bails
big
bigger
Language
unset
Current search:
fda
×
new
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
After 33 Exits in 5 Years, WI Seeks “More and Bigger” Startup Deals
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines